Stocks / BHVN vs WGS

BHVN vs WGS: Which Stock Is the Better Buy?

Biohaven Ltd. and GeneDx Holdings Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.

WGS is the larger company ($1.7B vs $1.7B). On the fundamentals, WGS has the stronger return on equity (-6.8% vs -1418.8%). On the filings, BHVN carries fewer potential red flags (1 vs 2). Full numbers below — the stronger figure on each row is in green.

AI verdict — BHVN vs WGS, read from the filings

The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.

 Biohaven Ltd. (BHVN)GeneDx Holdings Corp. (WGS)
Market cap$1.7B$1.7B
Revenue (latest FY)$0$427.54M
Net income (latest FY)$-738.82M$-21.02M
Revenue growth (5y CAGR)19.0%
Net margin-4.9%
Return on equity-1418.8%-6.8%
P/E ratio
Dividend yield
Profitable years (of last 10)00
Positive free cash flowNoYes

Verify the comparison

Use the filing period and source shown by each tool before treating two figures as comparable.

Compare with another company:

See the full BHVN vs WGS breakdown

Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.

Open BHVN's full financials →   Open WGS's full financials →

More comparisons

Frequently asked questions

Which is bigger, BHVN or WGS?

GeneDx Holdings Corp. is larger by market capitalization — $1.7B versus $1.7B.

Which grows faster, BHVN or WGS?

Five-year growth data is not available for both companies.

Where does this data come from?

All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.

Keep exploring

BHVN fundamentals → · WGS fundamentals → · All 1,500+ companies → · Free screener →